特比萘芬耐药性印度毛癣菌在欧洲出现的系统综述:行动时机已到?
本系统综述遵循PRISMA指南,检索PubMed、Scopus和Web of Science数据库,提取2019至2023年发表的16项研究,共描述欧洲63例由印度毛癣菌引起的抗真菌耐药皮肤癣菌病。所有病例的高特比萘芬MIC均与角鲨烯环氧化酶(SQLE)基因突变相关,伊曲康唑是最常用替代药物且换药后皮损完全缓解,但复发率令人担忧。作者建议实施监测计划并通过测序快速鉴定印度毛癣菌及SQLE突变,同时标准化抗真菌药敏试验流程以建立临床折点。
要点
- 欧洲已报告63例特比萘芬耐药印度毛癣菌感染,均与SQLE基因突变相关。
- 特比萘芬MIC范围0.014至≥16 μg/mL,但方法差异和缺乏临床折点使结果难以解读。
- 伊曲康唑换药后皮损可完全缓解,但复发率令人担忧。
核心结论
- 欧洲已出现特比萘芬耐药的印度毛癣菌,需通过监测和标准化药敏试验指导抗真菌药物合理使用。
研究设计与样本
- 遵循PRISMA指南的系统综述,检索PubMed、Scopus和Web of Science数据库,提取2019至2023年16项研究、共63例欧洲抗真菌耐药皮肤癣菌病病例。
主要发现
- 抗真菌药敏试验显示特比萘芬最低抑菌浓度(MIC)范围为0.014至≥16 μg/mL。
- 所有病例的高特比萘芬MIC均与角鲨烯环氧化酶(SQLE)基因突变相关。
- 伊曲康唑是本研究中特比萘芬最常用的替代药物,换药后皮损完全缓解,但复发率令人担忧。
关键数值与推荐
- 特比萘芬MIC范围0.014至≥16 μg/mL,但因方法差异和缺乏临床折点难以解读。
- 高特比萘芬MIC均与SQLE基因突变相关。
- 伊曲康唑换药后皮损完全缓解,但复发率令人担忧。
临床怎么用
- 建议实施监测计划,通过测序快速鉴定印度毛癣菌及SQLE突变。
- 建议标准化抗真菌药敏试验流程,以建立临床折点并指导抗真菌药物合理使用。
局限性
- 特比萘芬MIC值因所用方法差异及缺乏临床折点而难以解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is a recent growing global concern regarding the rise in antifungal resistance of dermatophytosis. The emergence of terbinafine-resistant Trichophyton indotineae (T. indotineae), previously known as Trichophyton mentagrophytes genotype VIII, is particularly alarming given that terbinafine is considered the treatment of choice for dermatophyte infections and the limited number of available antimycotics. This strain surfaced in the Indian subcontinent in the mid-2010s and more recently there have been reports of its arrival in Europe. OBJECTIVE: The objective of this review is to document the presence of terbinafine-resistant T. indotineae in Europe with the aim to guide antifungal stewardship and ultimately prevent the spread of resistance. METHODS: This study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A systematic literature search was performed using PubMed, Scopus and Web of Science databases. RESULTS: We extracted information from 16 studies published between 2019 and 2023 that described a total of 63 cases of antifungal-resistant dermatophytosis caused by T. indotineae in Europe. Antifungal susceptibility testing (AFST) revealed a wide range of terbinafine minimum inhibitory concentrations (MICs), varying from 0.014 to ≥16 μg/mL. However, these values are hard to interpret due to variations among used methodologies as well as the lack of clinical breakpoints. In all cases included in this study, elevated terbinafine MICs were associated with mutations in the squalene epoxidase (SQLE) gene. Itraconazole was the most frequently used alternative to terbinafine in this study and complete remission of tinea lesions after treatment switch was shown. Nevertheless, relapse rates are concerningly high. CONCLUSIONS: We propose the implementation of surveillance programmes for a fast identification through sequencing of T. indotineae (and SQLE mutations) and standardization of procedures for AFST to facilitate the establishment of clinical breakpoints and enable guidance on the appropriate use of antifungals.
引用
- Ferreira CB, Lisboa C. A systematic review on the emergence of terbinafine-resistant Trichophyton indotineae in Europe: Time to act? J Eur Acad Dermatol Venereol. 2024. PMID: 39082800. doi:10.1111/jdv.20270
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。